Toxicology News and Research RSS Feed - Toxicology News and Research

Toxicology is the study of harmful interactions between chemical, physical, or biological agents and biological systems.
Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. [More]
Hospitalization rates higher among people who live near hydraulic fracturing wells

Hospitalization rates higher among people who live near hydraulic fracturing wells

Hospitalizations for heart conditions, neurological illness, and other conditions were higher among people who live near unconventional gas and oil drilling (hydraulic fracturing), according to new research from the University of Pennsylvania and Columbia University published this week in PLOS ONE. [More]
Novel gene therapy control system regulates expression of therapeutic transgenes

Novel gene therapy control system regulates expression of therapeutic transgenes

Korean researchers have described a novel control system to regulate the expression of a therapeutic transgene by targeting the passenger strand of a microRNA (miR-122) linked to the transgene. [More]
Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects. [More]
Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute, a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI's cancer Nanotechnology Laboratory (caNanoLab) data portal. [More]
UC Davis scientists identify significant driver of neuropathic pain

UC Davis scientists identify significant driver of neuropathic pain

Scientists at the University of California, Davis, have identified a key mechanism in neuropathic pain. The discovery could eventually benefit millions of patients with chronic pain from trauma, diabetes, shingles, multiple sclerosis or other conditions that cause nerve damage. [More]
Discovery could pave way to new treatments for malaria

Discovery could pave way to new treatments for malaria

Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease. [More]
CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

Xybion Corporation, leading provider of preclinical R&D solutions announced today that CTI Biotechnology in Suzhou, China has implemented Xybion's Pristima 7 Preclinical Suite. Pristima® was selected after an exhaustive evaluation of top selling preclinical software systems on the market. [More]
Tiny aquatic flatworms could replace existing animal models used in neurotoxicity tests

Tiny aquatic flatworms could replace existing animal models used in neurotoxicity tests

Laboratories that test chemicals for neurological toxicity could reduce their use of laboratory mice and rats by replacing these animal models with tiny aquatic flatworms known as freshwater planarians. [More]
E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer. [More]
UB study sheds light on the molecular basis of cocaine addiction

UB study sheds light on the molecular basis of cocaine addiction

Researchers at the University at Buffalo have discovered a previously unknown neural pathway that can regulate changes made in the brain due to cocaine use, providing new insight into the molecular basis of cocaine addiction. [More]
ESCMID introduces two new study groups to create networks for forensic and veterinary microbiology

ESCMID introduces two new study groups to create networks for forensic and veterinary microbiology

The European Society of Clinical Microbiology and Infectious Diseases launched two new study groups; the Forensic and Postmortem Microbiology Study Group and the Veterinary Microbiology Study Group. [More]
Bio-Techne to acquire 100% ownership of Cliniqa

Bio-Techne to acquire 100% ownership of Cliniqa

Bio-Techne Corporation announced today that it has agreed to acquire 100% ownership of Cliniqa Corporation. Cliniqa specializes in the manufacturing and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market. [More]
Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Researchers have shown that a novel delivery strategy can efficiently introduce a functional microRNA that has anti-cancer and angiogenic activities into two different types of cells--breast cancer cells to inhibit tumor growth and metastasis, and cells that line blood vessels to protect against atherosclerosis. [More]
Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the Company’s versatile Vaxiclase platform. [More]

Alere announces cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock

Alere Inc., a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). [More]
Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research. [More]
Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose. [More]
TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US. [More]
Practical guidance to ensure safe use of flavourings in e-cigarettes

Practical guidance to ensure safe use of flavourings in e-cigarettes

The first practical guide to ensure the safe use of flavourings in e-cigarettes has been published. E-cigarettes and other vaping products contain a nicotine-based liquid that is vapourised and inhaled. There is no combustion so the user inhales vapour, not smoke. This means that e-cigarettes deliver nicotine without smoke toxicants. However, some in the public health community still have expressed concerns over the potential health impacts of flavourings used in e-cigarettes. [More]
Advertisement
Advertisement